Mary Beth Harler
About Mary Beth Harler
Mary Beth Harler is the SVP, Head of Immunology and Fibrosis Development at Bristol-Myers Squibb, with over a decade of experience in clinical development focusing on immunology and fibrosis.
Current Position at Bristol-Myers Squibb
Mary Beth Harler currently serves as the Senior Vice President (SVP) and Head of Immunology and Fibrosis Development at Bristol-Myers Squibb. In this role, she is responsible for overseeing the strategic direction and clinical development of innovative therapies aimed at treating immunological and fibrotic conditions.
Previous Roles at Bristol-Myers Squibb
Mary Beth Harler has held several significant leadership roles at Bristol-Myers Squibb. She was the SVP, Head of Innovative Medicines Development from 2017 to 2019, and the Head of Innovative Clinical Development (CV, IMM, Fibrosis, Genetically Defined Diseases) from 2016 to 2019. She began her tenure at the company as Executive Director Immunoscience from 2010 to 2014.
Experience in Clinical Development
With over a decade of experience in clinical development, Mary Beth Harler has focused on immunology and fibrosis. She has played a key role in the development of innovative clinical programs across diverse therapeutic areas such as cardiovascular, immunology, and genetically defined diseases, thereby contributing significantly to the advancement of Bristol-Myers Squibb's clinical development strategies.
Contributions to Immunoscience and Fibrosis
Mary Beth Harler has been instrumental in advancing Bristol-Myers Squibb's immunoscience clinical development strategies. Her efforts in leading clinical development teams and driving forward innovative therapeutic solutions have been pivotal in developing therapies aimed at treating immunology and fibrosis. She has also engaged in extensive research and translational medicine, leveraging data analytics to deliver personalized treatments.
Focus Areas in Research
Mary Beth Harler engages in cutting-edge research across multiple therapeutic areas, specifically focusing on immunology and fibrosis. Her work involves translational medicine and data analytics to not only advance the understanding of these conditions but also to develop personalized treatment options for patients.